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Abstract: Insulin resistance is a metabolic disorder in which target cells fail to respond to normal levels of cir-
culating insulin. Insulin resistance has been associated with presence of acanthosis nigricans and acrochor-
dons. It is known that early diagnosis and early initial treatment are of paramount importance to prevent a
series of future complications. These dermatoses may represent an easily identifiable sign of insulin resistan-
ce and non-insulin-dependent diabetes.
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Resumo: A resistência insulínica é uma alteração metabólica caracterizada por falhas das células-alvo em res-
ponder aos níveis normais de insulina circulante. A resistência insulínica já foi relacionada à presença de acan-
tose nigricante e de acrocórdons. Sabe-se que o diagnóstico e o início do tratamento precoce são de suma
importância para prevenção de uma série de manifestações futuras. Estas dermatoses podem representar um
sinal facilmente identificável para rastreamento de resistência à insulina e do diabetes mellitus não insulino-
dependente. 
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INTRODUCTION
1.1 Insulin Resistance
Insulin resistance (IR) is a metabolic disorder in
which target cells fail to respond to normal levels of
circulating insulin, which results in compensatory
hyperinsulinemia in an attempt to obtain an appro-
priate physiological response. 1 It is especially found
in individuals with diabetes mellitus (DM) type 2,
decompensated type 1 DM, diabetic ketoacidosis and
obesity.2-5 In normal populations, IR occurs in 20 to
25% of the individuals.2,5
There are three types of IR: (i) Type A, caused
by a reduced number and dysfunction of insulin
receptors; (ii) type B, caused by formation of antibo-
dies against insulin receptors; and (iii) Type C, which
corresponds to a post-receptor defect. Obese patients
and patients with polycystic ovary syndrome (PCOS)
have type-A insulin resistance. 6
DM occurs when insulin secretory capacity fails
to reduce serum glucose. Insulin concentrations are
generally higher in early type 2 diabetes, but the levels
are not enough to compensate for insulin resistance
due to a pancreatic beta cell defect. 6
Insulin resistance increases during puberty and
appears to be related to fat accumulation. 7
The insulin receptor belongs to the family of
tyrosine kinase receptors, which includes the insulin-
like growth factor (IGF), epidermal growth factor
(EGF), fibroblast growth factor (FGF), platelet-derived
growth factor, colony-stimulating factor I and several
cytokine receptors. 8,9 A high concentration of insulin
results in a direct and indirect activation of IGF-1
receptors in keratinocytes and fibroblasts, leading to
their proliferation. Other mediators can contribute,
including other tyrosine kinase receptors such as
EGFR - epithelial growth factor receptor - and FGFR-
fibroblast growth factor receptor. 10
Hyperinsulinemia increases ovarian androgen
production and IGF-1 and 2 in the liver. Insulin and
IGF-I increase the activity of 17-hydroxylase in the ova-
ries, causing excessive production of androgens, espe-
cially of 17-hydroxyprogesterone (17-OHP) (Figure 1).
Indirectly, insulin potentiates the action of LH in the
ovaries. 11,12 Another effect of the increase in insulin
levels is a decrease in the hepatic production of SHBG
(a sex-hormone carrier protein) and IGFBP-I (IGF-1
carrier protein or IGF-1 binding protein), contributing
to greater action of free testosterone (FT) and IGF-1,
respectively, in target cells. In vitro studies have
shown that insulin and IGF-1 may also stimulate
growth of the hair follicle and act together with andro-
gens when playing this role. Hyperinsulinemia can
also increase the action of 5-alpha reductase, leading
to increased conversion of testosterone into dihydro-
testosterone. 13
There are several methods of assessment and
diagnosis of IR. 1,5,14-15 Fasting insulin levels have been
used to assess IR, since it is easy to use this method in
large populations. Homeostasis Model Assessment
(HOMA) is a mathematical model that predicts IR by
simply measuring fasting glucose and insulin levels.
Also, it has good correlation with the hyperinsuline-
mic-euglycemic clamp method, which is considered
the gold standard for the measurement of IR. 1,14-15 Its
calculation for IR is done by multiplying the amount
of glucose (in mmol) by the amount of insulin (in
uU/mL) and dividing this result by 22.5 (HOMA-IR =
glucose (mmol) x insulin (uU/mL) ÷ 22.5). 1,5,14 - 15 IR is
FIGURE 1: Schematic demonstration of the effects of
hyperinsulinemia in various organs and tissues
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diagnosed when the result is greater than 2.71. 1 In
women, insulin resistance is considered when the
result exceeds the 75th percentile (1.80). 1 Direct met-
hods of assessment of IR include the insulin tolerance
test (KITT), insulin suppression test and hyperinsuli-
nemic-euglycemic clamp techniques. The costs of
their development, however, limit their use. 1
1.2 Acanthosis Nigricans 
Acanthosis nigricans (AN) was initially propo-
sed by Unna and then published by Pollitzer and
Janovsky in 1890. It is characterized by symmetrical,
hyperpigmented, velvety lesions, which can occur
anywhere in the body, but especially in the armpits,
groin, neck, antecubital and popliteal fossae and
umbilical region (Figure 2). Less often it affects eye-
lids, palms, soles of the feet, nipples and phalanges
(Figure 3). 16 In rare cases, it can affect the mucosa of
the mouth, respiratory mucosa and genital region.
These lesions may be skin-colored or brownish and
may vary between 1 mm and 1 cm. 6
Curth clinically classified AN as benign, malig-
nant, syndromic and pseudo-acanthosis nigricans
(Table 1). 17 The term pseudo-acanthosis nigricans was
reserved for cases in which the dermatosis affected
obese individuals who had no underlying endocrino-
pathies. In these cases, AN was attributed to excessive
local friction and sweat.17,18 However, later studies sho-
wed that AN was a marker for insulin resistance in
obese patients when compared with control groups
with similar degree of obesity. 19 With these findings,
the term pseudo-acanthosis nigricans became obsole-
te.
More recently, Sinha and Schwartz have propo-
sed a classification for AN as shown in Table 1. 20
The dermatological manifestation is similar in
all forms of AN, but AN tends to be less pronounced
in the juvenile type. The benign genetic form is rare
and it is an autosomal dominant disorder with incom-
plete penetrance. It can be present at birth or develop
during childhood. In this form, no endocrinopathy is
found. 6
Endocrinopathies are the major causes of AN,
and obesity is the most common disorder, often asso-
ciated with hyperinsulinism, diabetes mellitus and
insulin resistance. Other endocrine disorders associa-
ted with AN are described, such as Cushing’s syndro-
me, polycystic ovaries, thyroid diseases, hirsutism,
Addison’s disease, acromegaly, among others, some of
which occur with insulin resistance. 21
The mechanism through which insulin resistan-
ce causes acanthosis is complex. The significant pre-
sence of IR produces compensatory hyperinsulinemia.
Increased serum insulin levels interact with insulin-
like growth factor receptors (IGF-1) triggering prolife-
ration of keratinocytes and fibroblasts (Figure 4). AN
is caused by factors that stimulate epidermal keratino-
cyte and dermal fibroblast proliferation. In forms asso-
ciated with malignancy, substances secreted by the
tumor are thought to act as stimulating factors. 16 It is
postulated that TGF-alpha, which is produced by the
tumor and is similar to EGF, is important in the gene-
sis of malignant AN. 6,16,22
The epidermal growth factor (EGF) is an impor-
tant mediator of keratinocyte growth in vitro, and
both the EGF receptor (EGF-R) and EGF are found in
excessive amounts in the hyperproliferative epider-
mis. EGF needs to interact with insulin-like growth
factor/somatomedin (IGF-1) or with high doses of
insulin for keratinocyte proliferation. The IGF-I recep-
FIGURE 2: Acanthosis nigricans and skin tags FIGURE 3: Acanthosis nigricans; acral
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tor is located in the basal layer of the epidermis, sug-
gesting participation of IGF-1 and EGF in the regula-
tion of epidermal growth and in the pathogenesis of
hyperproliferative skin diseases.23
The prevalence of AN in unselected popula-
tions varies from 7 to 74%, according to age, race, fre-
quency of type, degree of obesity and concomitant
endocrinopathy. 24,25 In a study involving 34 obese indi-
viduals of both sexes in a predominantly black popu-
lation (59%), Hud et al. reported prevalence of AN in
74% of the patients and demonstrated clear predomi-
nance of AN in dark-skinned and black women in rela-
tion to white women. 19
Stoddart et al. (2002) and Kong et al. (2007)
recognized AN as an independent risk factor associa-
ted with hyperinsulinemia, with the development of
DM. 26,27 Kong showed that children with a family his-
tory of type 2 diabetes presented AN more often and
that acanthosis was more frequent in patients with
hypertension and high BMI. 27 This author concluded
that early detection of AN may be important in identi-
fying individuals at risk for type 2 diabetes, allowing
the doctor to advise a different lifestyle, thus reducing
the risk of developing the disease. 27
Several other studies have demonstrated an
association between  presence of AN and insulin resis-
tance, such as a study by Yamazaki et al. (2003). These
authors found a positive association between these
elements when investigating it among obese Japanese
children. 28 Stuart studied 89 African-Americans with
AN and observed a frequency of 21.3% of type II dia-
betes. 23 Burke et al. also observed higher levels of fas-
ting insulin in patients with AN. 29
Sadeghian et al. (2009) investigated the presen-
ce of insulin resistance in obese women with and wit-
hout AN, and the skin lesions proved to be a marker
for insulin resistance. The mean value of HOMA-IR
was 3.5 + -1.9 and 2.6 + -0.9um/ml in patients with
and without acanthosis nigricans, respectively (p
<0.05). There was no significant statistical difference
in terms of lipid profile, triglycerides and presence of
hypertension between the two groups. 22
Copeland et al. (2006) investigated the associa-
tion between AN and insulin resistance in children
and found that the intensity of the dermatological pre-
sentation was correlated with the values  of HOMA. 30
The same authors observed that AN showed to be an
independent risk factor for the development of insu-
lin resistance. 30 Wiegan et al. (2004) observed a sam-
ple of 491 obese children and adolescents and also
concluded that the presence of AN is associated with
higher HOMA values. 31 In addition to showing that
the HOMA index followed the intensity of AN, Araújo
et al. (2002) indicated that these changes in insulin
levels are found more often in dark-skinned and black
individuals, based on their sample of obese women.
Thus, the authors suggest that AN is a marker of high
risk for developing non insulin-dependent diabetes
mellitus. This study did not find statistical differences
in the proportions of total cholesterol, HDL, LDL and
triglycerides in the population with and without AN. 32
AN also showed to be more common in women
with polycystic ovary syndrome (PCOS). Charnvises et
al. confirmed in their study that AN is a cutaneous
marker of the presence of glucose intolerance and
insulin resistance in women with PCOS. 33
Hirschler et al. (2002) disagree in their study of
1,250 Hispanic children, stating that AN could reflect
obesity rather than represent an independent factor
for insulin resistance. 33 In this study, the BMI of
patients with AN was higher, but insulin resistance
and HOMA did not change compared to those without
acanthosis. 34
Caceres et al. (2008) studied the relationship
between insulin resistance and AN in obese children
and adolescents and found no statistically significant
association, since they found AN in 70% of the
patients with insulin resistance and in 54% of the
patients sensitive to insulin. 35 Scott suggested that AN
in obese children is a marker of metabolic dysfunc-
tion, since these patients presented an increased risk
of developing type 2 diabetes. In the same study, C-
reactive protein (CRP) levels were higher in the group
with AN, suggesting increased systemic inflammatory
response. This finding could not be confirmed becau-
se the method used for PCR detection was not the
same in all cases. 36
Hardin et al. (2006) suggested investigation of
DM focused on the presence of AN at the primary care
level. 37 Guran et al. (2008) suggest that AN may be a
FIGURE 4: Triggering mechanism of acanthosis nigricans lesions
associated with endocrinopathy 
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marker of metabolic syndrome (Syndrome X) in obese
children. Thus, children with this finding need to be
examined for syndrome X. 38 AN becomes a signal for
tracking insulin resistance and non-insulin-dependent
DM, with consequent changes in lifestyle and establis-
hment of early treatment. 27
Miura showed that AN is an important marker
of obesity associated with high body mass index, with
genes B2ADR Gly16 and B3ADR Arg 64 being synergis-
tically associated with AN in obese children and ado-
lescents. 39 The same group demonstrated higher
levels of alanine aminotransferase (ALT), reflecting
increased fat accumulation (steatosis) in the liver of
patients with AN. 40
Acanthosis can be treated simply by improving
lifestyle with regular physical activity and a proper
diet. For more extreme cases, we can use medication
such as octreotide (somastotatin analogue), analogues
of cholecalciferol (vitamin D3, topical calcipotriol,
retinoid and metformin). 6 Metformin reduces glucose
production by increasing peripheral insulin responsi-
veness. 41 The combined use of metformin and thiazo-
lidiones, which increase sensitivity to insulin in perip-
heral muscles, also presented good results. 42
In Texas (USA), the regional Education Agency
created a program for detection of type 2 diabetes in
1st, 3rd, 5th, and 7th graders in public and private
schools, which consisted in assessing the skin of these
students for AN between 1999 and 2003. The program
was simple and detection of the condition was easy,
since the exam was only clinical, not dependent on
invasive procedures. The children were diagnosed
and their parents were advised to take them to a doc-
tor for a thorough examination. 43
Sinha and Schwartz (2007) suggest how to
approach children with AN in their work (Figure 5). 20
1.2 Skin tags 
Skin tags are common tumors that usually affect
middle-aged individuals and the elderly. They usually
occur on the neck, armpits and groin. They are small
soft and pedunculated protrusions. 44-46 The lesions
may be brown or skin-colored and range from 1mm to
1cm in diameter. 47 Histologically, they are characteri-
zed by loss of collagen fibers and dilated blood capil-
laries. 48 After the age of 40, the frequency of skin tags
is 37%, being greater than in the general population,
among which the frequency is 20 to 25%. 49 Banik sta-
tes that, although 46% of the general population has
skin tags, only 14.4% have eight or more lesions on
the body. 48 In 2006, according to the region of the
country, it was estimated that between 0.9% and 1.2%
of the dermatologic diagnoses in Brazil referred to
skin tags.50
Multiple skin tags are frequently found in obese
and non-insulin-dependent diabetic individuals; insu-
lin resistance is an abnormality underlying the two
conditions. The proliferation of fibroblasts that occurs
in skin tags seems to be due to hyperinsulinemia, via
activation of the insulin-like growth factor (IGF-1)
receptors present on their surfaces. Skin tags are clo-
sely related to fasting insulin levels. 44
In recent years, some studies have tried to show
the correlation between skin tags and insulin resistan-
ce, their serum levels and the levels of IGF-1.
According to Jowkar et al., insulin levels in patients
with skin tags are far greater than in control indivi-
duals, suggesting the importance of insulin in their
pathogenesis. However, a correlation with levels of
IGF-1 has not been shown yet. 46 Similar to acanthosis
nigricans, insulin does not appear to be the only
mediator in the formation of skin tags, but it is certain-
ly the most important one in the formation of these
lesions. 51
Chart 1: Classification of acanthosis nigricans
Classification of acanthosis nigricans
(AN) according to Sinha and Schwartz:
obesity-associated AN (formerly termed
pseudo AN)
benign AN
syndromic AN
malignant AN
unilateral AN
acral AN
drug-induced AN 
mixed AN
Classification of acanthosis nigricans (AN) according to Curth:
Type I – malignant AN (cutaneous paraneoplastic syndrome)
Type II – benign AN/ true AN (present at birth or onset in childhood)
Type III – pseudo AN (association with endocrinopathies)
Type IV – drug-induced AN
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In individuals who have multiple skin tags, it is
important to suspect of a disorder in the metabolism
of carbohydrates, either in the form of insulin resis-
tance or diabetes mellitus. 45,46
Rasi et al. demonstrated that patients with
more than 30 skin tags are at higher risk of having dia-
betes (52%), although BMI was not correlated with
the number of skin tags in this study. 52
No correlation was found between the topo-
graphy of skin tags and carbohydrate metabolism,
except for skin tags in the inframammary region in
women. 51
Crook reported four patients with multiple skin
tags, and all patients had increased levels of serum tri-
glycerides and reduced HDL cholesterol levels. 53
Multiple skin tags (more than 8 lesions) were more
sensitive than AN when identifying changes in carbo-
hydrate metabolism, but less specific. 52 Therefore,
presence of skin tags is a clue for detection of hype-
rinsulinemia, which is considered the foundation for
syndrome X. 51
Tamega et al. identified an independent asso-
ciation between presence of more than five skin tags
and an increase of 1.4 units in the HOMA-IR index in
dermatological patients. The significant association
with BMI and hypertriglyceridemia found in this study
strengthens the concept that skin tags may constitute
markers of insulin resistance. 54
HPV infections are associated with the genesis
of several benign lesions. In a study by Dianzani
(1998), the presence of HPV 6/11 DNA was detected
in 88% of skin tags; however, the amount of DNA was
small in these cases. 55 Gupta performed PCR for HPV
types 6 and 11 in skin tags and found the presence of
HPV 6/11 DNA in 48.6% of the soft fibromas. However,
more studies are needed to confirm the role of HPV in
the formation of skin tags. 56
Presence of skin tags is associated with preg-
nancy, acromegaly, intestinal polyps, dyslipidemia and
several syndromes: polycystic ovary, Birt-Hogg-Dube
and Cowden syndromes. 57 Variations in estrogen
levels are implicated in the etiology of these lesions. 54
Rezzonico et al. concluded that individuals with
skin tags have a high prevalence of thyroid nodules
and thyroid with increased volume. 58 This is because
skin tags and thyroid changes may be associated with
high levels of circulating insulin. 58
CONCLUDING REMARKS
AN lesions and skin tags should never be igno-
red, since they bring information about internal disea-
ses and, therefore, can offer some guidance as to how
to proceed about these diseases, preventing a series of
future morbidities such as diabetes and atherosclero-
tic diseases.
Although often disregarded by patients, since
they are asymptomatic lesions, these dermatoses are
of great importance and cannot go unnoticed in the
clinical examination, since they can serve as indicators
of the need to measure laboratory data that may lead
to a diagnosis of insulin resistance.
IR, like smoking, alcohol abuse and violence in
traffic, represent one of the most important modifia-
ble factors for promoting health and reducing morta-
lity in general. 54
Insulin resistance has been associated with AN
and AC, and it is known that early diagnosis and early
treatment are of paramount importance to prevent a
FIGURE 5: Approach of children with acanthosis
nigricans 20
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series of future manifestations. Reduction of insulin
action may be accompanied by a group of metabolic
disorders such as hypertension, hypertriglyceridemia,
reduced HDL/cholesterol levels, carbohydrate intole-
rance, central obesity, increased plasminogen activa-
tor inhibitor-1 concentrations (fibrinolytic disorders),
hyperuricemia and atherosclerotic cardiovascular
disease. This set of changes is known as insulin resis-
tance syndrome or metabolic syndrome. 2,5 Therefore,
AN becomes an easy signal for tracking insulin resis-
tance and non-insulin-dependent DM, with implica-
tions regarding changes in lifestyle and adoption of
early treatment. 59 ❑
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